Study links gene mutation to miscarriage risk:
This article was originally published in Clinica
Executive Summary
A genetic mutation that predisposes women to developing blood clots, has been linked with an increased risk of miscarrying during pregnancy at around 12 weeks, says a team at St Mary's Hospital NHS Trust, In London. Results from a trial show that just 40% of women with a history of recurrent miscarriage and mutation on their Factor V gene, known as Factor V Leiden, had live births, compared with 70% of women with a similar history but with a normal Factor V gene. The findings appear in Human Reproduction (January 30).
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.